46 min.


This webinar will address preoperative biomarker testing and issues around neoadjuvant immunotherapy for NSCLC. Neoadjuvant immunotherapy for early stage NSCLC represents a paradigm shift in treatment approaches, while biomarker testing is critical for decision-making. Presenters will discuss nuanced issues regarding patient selection and how to address patient concerns with delaying surgery to undergo neoadjuvant therapy. 

Part 2 of a 2-part webinar series, supported by AstraZeneca. (View part 1, "Sublobar Resection Versus Lobectomy for Early-Stage Lung Cancer: A Debate".)


Robert E. Merritt, MD
The Ohio State University
Columbus, OH

Sandra L. Starnes, MD
University of Cincinnati Medical Center
Cincinnati, OH

Hari B. Keshava, MD
University of California, Irvine
Irvine, CA


Biomarker Testing
Dwight H. Owen, MD, MS
The Ohio State University
Columbus, OH

Neoadjuvant Immunotherapy
Jessica S. Donington, MD, MSCR
University of Chicago
Chicago, IL